PPI Statement on the FDA’s Modified Risk Assessment of IQOs
PPI strongly supports science-based regulatory policy, no matter where the evidence leads us. This means tackling tough problems with an open and pragmatic mind to achieve the best possible outcomes. Moreover, we place a high premium on clear communication of information relevant for public health, especially in today’s turbulent times.
From that perspective, we applaud the FDA’s authorization of “the marketing of Philip Morris Products S.A.’s “IQOS Tobacco Heating System” as modified risk tobacco products (MRTPs).”
These are the first tobacco products to receive what the FDA calls an “exposure modification order.” That permits “the marketing of a product as containing a reduced level of or presenting a reduced exposure to a substance or as being free of a substance when the issuance of the order is expected to benefit the health of the population.”
In other words, the FDA specified precise language that the manufacturer could use, including that “switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.” And that’s a good thing!